liver

The limits of classical equivalent computation based on time, dose, and fractionation (TDF) and linear quadratic models have been known for a long time. Medical physicists and physicians are required to provide fast and reliable interpretations regarding the delivered doses or any future prescriptions relating to treatment changes. In this letter, we propose an outline related to the different models usable for equivalent and biological doses that are likely to be the most appropriate. The used methodology is based on: the linear-quadratic-linear model of Astrahan, the repopulation effects of Dale, and the prediction of multi-fractionated treatments of Thames.

This article provides a comprehensive overview of the properties, applications, and fabrication techniques of nanofibers, which are characterized by their ultrafine diameters and unique features such as high surface area and aspect ratio. These attributes render nanofibers particularly advantageous for a wide range of applications, especially in the biomedical sector, encompassing areas like tissue engineering, drug delivery, and wound dressing. The article highlights various studies that illustrate the potential of nanofibers in addressing healthcare challenges, particularly their utilization in scaffolds for regenerative medicine and as carriers for controlled drug delivery. Furthermore, it discusses different preparation methods for nanofibers, including electrospinning and alternative techniques, while stressing the importance of polymer selection in achieving optimal drug-release properties. The article also delves into the application of nanofibers in tissue engineering, specifically for bone, cartilage, and vascular applications, and examines their emerging roles in organ-on-a-chip technology and contraceptive development. In conclusion, the article emphasizes the versatility and significance of nanofibers in advancing medical technologies and their potential to address contemporary health challenges. Collaborative efforts between material scientists and biologists are essential to foster interdisciplinary research aimed at improving electrospinning methodologies.

Background: Monotherapy for liver dysfunction in diabetes is less effective. This study investigated the effect of combined linagliptin and metformin therapy on liver function in diabetic rats. Methods and materials: Sixty-four mature male (200-300 g) Wistar rats were used. Streptozotocin (35 mg/kgb.wt) was repeatedly injected intraperitoneally to induce diabetes. The rats were grouped into eight groups (n = 8). Group I: control; Group II: control + 10 mg/kgb.wt linagliptin; Group III: control + 200 mg/kgb.wt metformin; Group IV; control + 10 mg/kgb.wt linagliptin + 200 mg/kgb.wt metformin; Group V: diabetic; Group VI: diabetic + 10 mg/kgb.wt linagliptin; Group VII: diabetic + 200 mg/kgb.wt metformin; Group VIII: diabetic + 10 mg/kgb.wt linagliptin + 200 mg/kgb.wt metformin. The animals were sacrificed on the last day of the experiment, blood and liver samples were collected for biochemical assay. Results: Insulin, blood glucose, glycated hemoglobin, total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-cholesterol), liver function biomarkers, liver glucose metabolic enzymes, malondialdehyde and inflammatory markers increased (p < 0.05) significantly. High-density lipoprotein-cholesterol (HDL-cholesterol), liver antioxidant, glycogen, and glycogen synthase were reduced significantly in diabetic rats. Linagliptin and metformin administration single and combined reduced the insulin, blood glucose, glycated hemoglobin, total cholesterol, triglycerides, LDL-cholesterol, liver function biomarkers, liver glucose metabolic enzymes, malondialdehyde, and inflammatory markers, and increased the HDL-cholesterol, liver antioxidant, glycogen and glycogen synthase in diabetic rats.Conclusion: Linagliptin monotherapy alone efficiently controls hyperglycemia and remarkably improves liver functions. Combining linagliptin and metformin could be used as safe and effective therapy for liver dysfunction progression in diabetes.

Preterm birth, defined as delivery before 37 weeks of gestation, remains a leading cause of neonatal morbidity and mortality globally. One of the developmental challenges in preterm infants is the immaturity of the sucking-swallowing-breathing triad, which hinders successful oral feeding. Non-Nutritive Sucking (NNS) is an innate reflex in neonates that involves sucking motions without the intake of nutrition. This behaviour, often facilitated by pacifiers or a gloved finger, plays a vital role in neurodevelopment, feeding maturity, and physiological regulation in preterm infants. Recent studies also highlight its psychological and lactational benefits for mothers. This review presents a synthesis of current evidence supporting NNS as a low-cost, non-invasive intervention with multidimensional benefits for both preterm infants and their mothers.